Article
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
The oncologist - 1 Jul 2014
Khozin Sean, Blumenthal Gideon M, Jiang Xiaoping, He Kun, Boyd Karen, Murgo Anthony, Justice Robert, Keegan Patricia, Pazdur Richard
Abstract excerpt
On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva, Astellas Pharma Inc., Northbrook, IL, http://www.us.astellas.com/) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. This indication for erlotinib was approved...
Topics
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Non-Small-Cell Lung
- Disease-Free Survival
- Drug Approval
- ErbB Receptors
- Erlotinib Hydrochloride
- Exons
- Female